PharmacyCodes



Lopirin [Switzerland] en es it fr

Categoria

Lopirin [Switzerland] Nombres de marca, Lopirin [Switzerland] Analogos

Lopirin [Switzerland] Marca los nombres de mezcla

  • No information avaliable

    • Lopirin [Switzerland] Formula quimica

    C9H15NO3S

    Lopirin [Switzerland] RX enlace

    http://www.rxlist.com/cgi/generic/captop.htm

    Lopirin [Switzerland] FDA hoja

    Lopirin [Switzerland] MSDS (hoja de seguridad de materiales)

    Lopirin_[Switzerland] MSDS

    Lopirin [Switzerland] Sintesis de referencia

    DW Cushman, EE.UU. Pat. 4,046,889 (1977)

    Lopirin [Switzerland] Peso molecular

    217.286 g/mol

    Lopirin [Switzerland] Punto de fusion

    106oC

    Lopirin [Switzerland] H2O Solubilidad

    Muy soluble

    Lopirin [Switzerland] Estado

    Solid

    Lopirin [Switzerland] LogP

    0.546

    Lopirin [Switzerland] Formas de dosificacion

    Tablet (12,5 mg, 25 mg, 50 mg o 100 mg)

    Lopirin [Switzerland] Indicacion

    Para el tratamiento de la hipertensión. Se puede utilizar solo o en combinación con diuréticos tiazídicos.

    Lopirin [Switzerland] Farmacologia

    Captopril, un inhibidor de la enzima convertidora de angiotensina (ECA), se utiliza para tratar la hipertensión, insuficiencia cardiaca congestiva, y síndromes renales como la nefropatía diabética y la esclerodermia. El efecto adverso y las limitaciones farmacocinéticas del captopril estimulado el desarrollo de inhibidores de la ECA enalapril y posteriores.

    Lopirin [Switzerland] Absorcion

    75% sin alimentos (la presencia de alimentos en el tracto gastrointestinal reduce la absorción de unos 30 a 40 por ciento).

    Lopirin [Switzerland] Toxicidad

    Los síntomas de sobredosis incluyen coma, letargo, baja presión arterial, la lentitud, y el estómago e irritación intestinal y la hiperactividad.

    Lopirin [Switzerland] Informacion de Pacientes

    Patients should be advised to immediately report to their physician any signs or symptoms suggesting angioedema (e.g., swelling of face, eyes, lips, tongue, larynx and extremities; difficulty in swallowing or breathing; hoarseness) and to discontinue therapy.

    Patients should be told to report promptly any indication of infection (e.g., sore throat, fever),which may be a sign of neutropenia, or of progressive edema which might be related to proteinuria and nephrotic syndrome.

    All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

    Patients should be advised not to use potassium-sparing diuret-ics, potassium supplements or potassium-containing salt substitutes without consulting their physician.

    Patients should be warned against interruption or discontinuation of medication unless instructed by the physician.

    Heart failure patients on captopril therapy should be cautioned against rapid increases in physical activity.

    Patients should be informed that captopril should be taken one hour before meals.

    Lopirin [Switzerland] Organismos afectados

    Humanos y otros mamíferos